Chinese pharmaceutical companies are buying up expiring United States drug patents in a bid to accelerate expansion drives.
US sellers are usually very wary of expanding into China's market, known for widespread and flagrant intellectual property rights violations, but for a royalty they are increasingly willing to sell expiring patents to Chinese drugmakers.
The target market is domestic but some Chinese pharmaceutical firms plan to produce the drugs for export to other Asian countries.